

Toxic Substances Control Act: *Data Needs and Prospects for Reform*

Richard A. Denison, Ph.D.

Senior Scientist


Chemical Watch Regulatory Summit

December 5, 2013



What's changed since 1976?

- Chemical production: 25x ↑ globally, \$171 billion in 1970 to \$4.1 trillion in 2010
 - Growth in #, types of chemicals has been less dramatic



Source: Wilson and Schwarzman (2008) *Green Chemistry: Cornerstone to a Sustainable California*, University of California, based on data from American Chemistry Council 2003; OECD 2001; United Nations 2004

- ↑ diversity of use: especially in consumer products and building materials
 - Used to make 96% of all materials and products

What's changed since 1976?

- Understanding of extent and pathways of chemical exposures
 - Advent of biomonitoring
 - Long-range transport, importance of airborne as well as waterborne pathways for both movement and uptake
 - Migration of chemicals from products into environment, people
 - Coal tar-based sealants used on parking lots
 - BFRs in furniture foam
 - Disproportional exposures: Environmental justice issues

What's changed since 1976?

- Science drivers: Connecting the dots
 - Certain chronic diseases are on the rise
 - Certain chemicals linked to those same chronic diseases
 - Many of those same chemicals are in us
- Growing recognition of importance of:
 - Early-life exposures
 - Low-dose effects (endocrine disruption)
 - Epigenetics – is it a basis for explaining/elucidating:
 - early-life exposures → later-life disease outcomes?
 - variability in susceptibility?
 - transgenerational effects?

What's changed since 1976?

- Risk assessment evolution and controversy
 - Red Book (1983) → Silver Book (2009)
 - Human variability
 - Uncertainty
 - D-R: Cancer vs. non-cancer effects
 - Should no-effect thresholds be presumed to exist across a diverse human population?
 - Cumulative effects and exposures
 - Multiple chemicals
 - Chemicals and other stressors

What's changed since 1976?

- Emerging high-throughput testing: Tox21
 - Potential to:
 - address huge backlog of untested chemicals
 - increase human relevance
 - identify biomarkers of exposure to specific chemicals
 - consider multiple cell types and life stages
 - test at many different doses
 - assess mixtures
 - inform green chemistry
- 

What's changed since 1976?

- Emerging high-throughput testing: Tox21
 - Challenges
 - *In vitro* vs. *in vivo*
 - Can all potential effects pathways ever be captured?
 - How to account for real world: multiple exposures at different times, chronic exposures
 - Determining whether a perturbation is adverse
 - False positives vs. negatives

TSCA: Problems with current paradigm

Existing chemicals

- Presumption of innocence: TSCA grandfathered 62,000 chemicals
 - Default: No or uncertain info = No action
 - High hurdle to require testing
 - Proof of harm needed to regulate
 - Government shoulders burden of proof
 - Contrast to pesticides, drugs
- 

TSCA, the Dog that Didn't Even Bark



By the numbers:

- **62,000** chemicals grandfathered in when TSCA was passed in 1976
- Required testing on **<300** in 37 years
- **5** of these chemicals have been regulated in limited ways
- **22 years** since EPA last tried (and failed) to regulate a chemical: *asbestos*

TSCA: Problems with current paradigm

New chemicals

- ***No data, no problem***: No up-front testing requirement or minimum data set
 - Unlike virtually every other developed country in world
- ***Guessing game***: EPA is forced to heavily rely on limited prediction models
 - No reliable models for most mammalian tox endpoints
- ***Catch-22***: To require testing, EPA must first show potential risk or high exposure

TSCA: Problems with current paradigm

New chemicals

- ***One bite at the apple***: EPA typically gets only a single review opportunity
- ***Crystal-ball gazing***: EPA must anticipate future production and use
- ***Black box***: New chemical reviews lack transparency
- ***Anti-precaution***: Lack of evidence of harm taken as evidence of no harm

TSCA: Lack of production/use/exposure data

- Collected only from manufacturers under CDR
 - Subset of estimated 30-50,000 chems in commerce
 - reporting threshold is $\geq 25,000$ lbs/yr/site
 - many reporting exemptions
 - 2012: ca. 7,700 chemicals reported made/imported
- Use information still very limited
 - Use reporting threshold is $\geq 100,000$ lbs/yr/site
 - 2012: ca. 3,600 chemicals reported comm/cons use
 - For 74% of these, at least one of the 6 reportable consumer/commercial use data items was reported as “not known or reasonably ascertainable”

Broader lack of use/exposure data

- EPA's Aggregated Computational Toxicology Resource (ACToR) database:
 - 550,000 chemicals
 - only 4% have *any* exposure-related data
 - 90% of these have only one type of such data (usually production volume)
 - only 1.4% have *any* use information
 - Of 700 ACToR chemicals of concern for children, only 185 have any exposure-related information

Source: Egeghy et al. (2012) "The exposure data landscape for manufactured chemicals" *Science of the Total Environment*

Limited availability of hazard data

- ca. 9,900 ACToR chemicals examined
 - HPV and MPV chemicals
 - pesticide and antimicrobial active and inert ingredients
 - air and drinking water pollutants
 - IRIS chemicals
 - TRI chemicals
 - EDSP chemicals
- $< \frac{2}{3}$ have even limited hazard information
- $\approx \frac{1}{4}$ have detailed toxicology information

Source: Judson et al. (2009) "The toxicity data landscape for environmental chemicals," *Environmental Health Perspectives*

Limited availability of hazard data

For the 9,900 chemicals:

Hazard data	58.6%
– Carcinogenicity	26.0
– Genotoxicity	27.5
– Developmental toxicity	28.9
– Reproductive toxicity	10.9

Source: Judson et al. (2009) “The toxicity data landscape for environmental chemicals,” *Environmental Health Perspectives*

Time for a paradigm shift

- Current: Unless there is evidence of harm, assume safety and don't look any further
 - Needed: Require affirmative evidence of safety to enter or remain on the market
- 

TSCA reform legislation in 2013

- April 10: Safe Chemicals Act (S. 696)
 - Lead sponsor Lautenberg, 28 co-sponsors (all Ds)
 - May 22: Chemical Safety Improvement Act (S. 1009)
 - Lead sponsors Lautenberg and Vitter, 25 co-sponsors (12 Ds, 13 Rs)
- 

TSCA reform legislation in 2013

- April 10: Safe Chemicals Act (S. 696)
 - Lead sponsor Lautenberg, 28 co-sponsors (all Ds)
- *ca. May 1: “The Vitter Bill”*
 - *Lead sponsor Vitter, ?? co-sponsors (likely 2-3 Ds)*
- May 22: Chemical Safety Improvement Act (S. 1009)
 - Lead sponsors Lautenberg and Vitter, 25 co-sponsors (12 Ds, 13 Rs)
- June 3: Lautenberg dies

Positive aspects of CSIA

- For first time, safety reviews mandated for all chemicals
- New chemicals must be found likely to meet the safety standard before being made and sold
- States, medical personnel gain access to CBI
- Addresses two main reasons TSCA's safety standard failed:
 - Replaces cost-benefit requirement with a health-only standard
 - But not for bans/phaseouts
 - Strikes “least burdensome” requirement (led to paralysis-by-analysis)
 - But requires potentially endless analysis of alternatives
- Eases EPA's ability to get new data:
 - Provides for test orders
 - Strikes TSCA's “Catch-22” that EPA show risk to require testing

Major concerns with CSIA

- Standard doesn't ensure protection of vulnerable populations
- Doesn't ensure all claimed CBI merits trade secret protections
- Bars testing of a new chemical or for prioritization
- Lacks deadlines, imposes excessive procedural requirements
 - Conservative estimates – Date of enactment to:
 - 1st prioritized chemicals = 39 months or 3.25 years
 - 1st safety determination = 86 months or 7.17 years
 - 1st final risk mgmt rule = 104 months or 8.67 years

Major concerns with CSIA, cont'd.

- Sweeping pre-emption of state authority
 - States can't enact same requirements as EPA to allow for co-enforcement
 - “Restriction” can be read broadly to apply to warning labels (e.g., CA Prop 65), monitoring, release limits, other purposes (e.g., GHG limits)
 - Pre-emption of new requirements triggered long before EPA acts to identify/control risks
 - Low-priority: No judicial review, yet final agency action
 - High-priority: Start of safety determination years before action
 - Pre-emption of existing requirements triggered by safety determination
 - should be final risk management rule for such chemicals

Key improvements needed

- more deadlines, fewer procedural requirements
 - defining and explicitly protecting vulnerable populations
 - narrowing the bill's preemption of state authority to ensure that states can act when EPA does not
 - ensuring low-priority designations of chemicals are based on sufficient hazard and exposure information and do not preempt state authority
 - providing EPA with adequate resources, with a fair share coming from industry
- 

For more information

EDF's Chemicals Policy Webpage

www.edf.org/health/policy/chemicals-policy-reform

EDFHealth Blog

<http://blogs.edf.org/health/>

